The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Cuban annual raw sugar production will fall below 200,000 metric tons in 2025 for the first time since the 19th century, ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...